General Catalyst: Pro-Competitive Partnerships Drive “Steady Drumbeat of Innovation” in the Life Sciences

Investment in early-stage life sciences companies is critical to sustain America’s global leadership in discovering and developing new medical breakthroughs for patients, according to a recent General Catalyst blog, “The Future of Life Sciences Investment.” Early-stage life sciences companies are unique for their ability to leverage specialized scientific knowledge and a nimble structure to pursue new, innovative approaches to treat a disease. However, these companies often rely on external investment, such as from venture capital (VC), to be able navigate the cost pressures and considerable risks associated with early-stage drug development.


Life sciences mergers and acquisitions (M&A) represent a clear exit point for VC investors, attracting investment and allowing companies of all sizes to combine their complementary resources, skills and expertise to bring new medicines to patients. Amidst an increasingly challenging investment landscape, preserving M&A is critical to continue supporting the hundreds of pre-clinical companies working to bring new therapies to patients. 


Highlights from the blog are included below:

  • “Over the past decade, the biopharmaceutical industry has quietly produced a steady drumbeat of significant medical advances…Despite these advances, there’s global pressure to innovate faster. While the U.S. has historically been the global leader in scientific research and development, it now faces increased international competition…”
  • “For America to maintain its competitive advantage, it must continue investing in research and clinical development… We believe that venture capital can meaningfully contribute to fill this investment gap, providing support for America’s continued ability to innovate and advance global human health."
  • “This isn’t just our belief — venture-backed companies are driving enhanced R&D productivity and efficiency. Recent data shows that roughly 65% of new medicines originated from outside of large pharmaceutical companies.”
  • “We believe the most meaningful breakthroughs in life sciences are rarely achieved in isolation. They’re the result of deep, sustained collaboration — between scientists and clinicians, industry and academia, and increasingly, founders and investors.”


As this blog highlights, life sciences M&A remains a critical pathway for fueling investment and supporting America’s role as a global leader in life sciences innovation. Policymakers must recognize the value of life science M&A and support enforcement policies that encourage these pro-competitive partnerships and the innovative medicines they bring to patients.


About the Partnership for U.S. Life Science Ecosystem (PULSE)

The U.S. life sciences ecosystem depends on mergers and acquisitions (M&A) as well as other collaborations to bring together the resources, investment and expertise needed to develop and deliver new treatments and cures for patients. PULSE is dedicated to raising awareness about the unique life sciences ecosystem and the importance of M&A in leveraging efficiency and experience across companies of all sizes. PULSE will help advance a national dialogue focused on fostering innovation across the life sciences while supporting a competitive U.S. market that advances next generation treatments and cures for patients. For more information, visit https://pulseforinnovation.org/.

Georgia’s Life Sciences Momentum is Getting Noticed Nationally.

August 21, 2026
Genetic Engineering & Biotechnology News (GEN) has named Georgia #4 among its “Next 5 States” for emerging U.S. biopharma clusters . The article highlights UCB’s planned $2 billion investment at in Gwinnett County, Micron Biomedical’s new Alpharetta facility, Manus Bio’s expansion in Augusta, Science Square, Emory University, the CDC — and Georgia Life Sciences’ 10-year Life Sciences Roadmap . This recognition is exciting. But even more importantly, it validates the work happening across our entire ecosystem — and perfect momentum as we head into the 2026 Georgia Life Sciences Summit next week. Read more by visiting: Next 10 U.S. Biopharma Clusters

BIO Supports PDUFA VIII Commitment Letter and Urges Timely Reauthorization

August 17, 2026
Biotechnology Innovation Organization (BIO) Senior Vice President of Science & Regulatory Affairs Annetta Beauregard issued the following statement on the release of the Prescription Drug User Fee Act (PDUFA) VIII commitment letter: “For more than 30 years, PDUFA has helped deliver hundreds of new medicines to American patients. As a lead industry negotiator for the PDUFA VIII agreement, BIO supports the PDUFA VIII commitment letter and its strengthening of regulatory review, advancing innovation, and helping deliver safe and effective treatments to patients. “Specifically, the PDUFA VIII agreement includes important commitments that bolster the FDA’s core review activities, ensure accountability for predictable performance, improve financial sustainability and improve communication, transparency and efficiency. “Timely, bipartisan reauthorization of PDUFA is vital for protecting the health of Americans, strengthening U.S. competitiveness, and maintaining America’s global leadership in medical innovation. BIO is committed to working with Congress to ensure reauthorization by September 30, 2027.” The FDA has announced plans to hold a hybrid public meeting at 9am on 9/16 to discuss the proposed enhancements for the reauthorization of PDUFA for fiscal years (FYs) 2028 through 2033. Learn More about PDUFA and the PDUFA VIII commitment letter HERE .

Georgia Life Sciences Submits Comments on Medicare Drug Price Negotiation Program

August 17, 2026
Representing Georgia’s life sciences community, GLS emphasized the importance of advancing policies that improve affordability and patient access while preserving the environment necessary for continued biomedical innovation. In its comments, GLS urged CMS to maintain a framework grounded in FDA regulatory determinations and raised concerns about how certain proposed policies could affect post-approval research and development, investment in new indications, and patient access to innovative therapies. GLS also encouraged CMS to consider the broader implications for healthcare delivery, including the potential impact on patients and providers in rural and underserved communities. As federal drug pricing policy continues to evolve, Georgia Life Sciences will continue to advocate for approaches that balance affordability, access, and innovation while ensuring Georgia’s life sciences community has a voice in the policymaking process. Read Georgia Life Sciences’ full comments to CMS ( click here ).
MORE POSTS